Adhikary Till, Wortmann Annika, Finkernagel Florian, Lieber Sonja, Nist Andrea, Stiewe Thorsten, Wagner Uwe, Müller-Brüsselbach Sabine, Reinartz Silke, Müller Rolf
Institute of Molecular Biology and Tumor Research (IMT), Center for Tumor Biology and Immunology (ZTI), Philipps University, Marburg, Germany.
Genomics Core Facility, Center for Tumor Biology and Immunology (ZTI), Philipps University, Marburg, Germany.
BMC Genomics. 2017 Mar 21;18(1):243. doi: 10.1186/s12864-017-3630-9.
Although tumor-associated macrophages (TAMs) are essential for cancer progression, connections between different clinical outcomes and transcriptional networks have not been reported. We have addressed this issue by analyzing global expression patterns of TAMs isolated from the ascites of ovarian cancer patients.
TAMs isolated from different ovarian cancer patients can be stratified by coexpression or principal component analysis into subgroups with specific biological features and associated with distinct clinical outcomes. A hallmark of subgroup A is a high expression of clinically unfavorable markers, including (i) high CD163 expression, a surface receptor characteristic of an anti-inflammatory activation state, (ii) increased PCOLCE2 expression, indicative of enhanced extracellular matrix organization, and (iii) elevated ascites levels of IL-6 and IL-10, linked to the aggressiveness of ovarian cancer and immune suppression. In contrast, subgroup B TAMs are characterized by the upregulation of genes linked to immune defense mechanisms and interferon (IFN) signaling. Intriguingly, analysis of published data for 1763 ovarian cancer patients revealed a strong association of this transcriptional signature with a longer overall survival. Consistent with these results, IFNγ was able to abrogate the suppressive effect of ovarian cancer ascites on the inducibility of IL12B expression and IL-12 secretion, a key determinant of a cytotoxic immune response.
The survival of ovarian cancer patients is linked to the presence of TAMs with a transcriptional signature that is characterized by a low expression of protumorigenic and immunosuppressive markers and an upregulation of genes linked to interferon signaling. The observed IFNγ-mediated restoration of the inducibility of IL-12 in the presence of ascites provides a possible explanation for the association of an interferon signaling-associated signature with a favorable clinical outcome.
尽管肿瘤相关巨噬细胞(TAM)对癌症进展至关重要,但不同临床结局与转录网络之间的联系尚未见报道。我们通过分析从卵巢癌患者腹水中分离出的TAM的整体表达模式来解决这一问题。
从不同卵巢癌患者分离出的TAM可通过共表达或主成分分析分层为具有特定生物学特征且与不同临床结局相关的亚组。A亚组的一个标志是临床不良标志物的高表达,包括:(i)CD163高表达,这是抗炎激活状态的表面受体特征;(ii)PCOLCE2表达增加,表明细胞外基质组织增强;(iii)腹水中IL-6和IL-10水平升高,这与卵巢癌的侵袭性和免疫抑制有关。相比之下,B亚组TAM的特征是与免疫防御机制和干扰素(IFN)信号相关的基因上调。有趣的是,对1763例卵巢癌患者的已发表数据进行分析发现,这种转录特征与更长的总生存期密切相关。与这些结果一致,IFNγ能够消除卵巢癌腹水对IL12B表达诱导和IL-12分泌的抑制作用,而IL-12分泌是细胞毒性免疫反应的关键决定因素。
卵巢癌患者的生存与具有特定转录特征的TAM的存在有关,该特征表现为促肿瘤和免疫抑制标志物低表达以及与干扰素信号相关的基因上调。在腹水存在的情况下观察到的IFNγ介导的IL-12诱导恢复,为干扰素信号相关特征与良好临床结局之间的关联提供了一种可能的解释。